Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00840450 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00840450 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 14 participants.
The verdict
NCT00840450, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.
Interventions
- DRUG Gleevec/Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00840450
The ClinicalTrials.gov registry entry for NCT00840450 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gleevec/Paclitaxel is the first listed.
NCT00840450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00840450 about?
NCT00840450 is a clinical study titled "Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin". This study is designed to determine whether the combination treatment of Paclitaxel and Gleevec on recurrent ovarian cancer patients or other cancers of mullerian origin will generate better clinical response than Paclitaxel alone.
What is the current status of trial NCT00840450?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-04. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00840450?
The interventions under investigation include: Gleevec/Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00840450?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.